



European  
Commission

*Certificate delivered by the European Commission,  
as the institution managing Horizon 2020,  
the EU Framework Programme for Research and Innovation 2014-2020*

The project proposal **735995, THAMAR**

**Development of the CDK inhibitor VS2-370 to target HIV-  
associated malignancies and to purge viral reservoir**

Submitted under the Horizon 2020's **SME instrument phase 1**  
call **H2020-SMEInst-2016-2017 (H2020-SMEINST-1-2016-2017)** of **3 May 2016**  
in the area of

**Dedicated support to biotechnology SMEs closing the gap from lab to market**

by

**VIROSTATICS SRL**

VIALE UMBERTO I 46

07100 SASSARI

Italy

following evaluation by an international panel of independent experts

**WAS SUCCESSFUL IN A HIGHLY COMPETITIVE EVALUATION PROCESS\*  
AS AN INNOVATIVE PROJECT PROPOSAL**

This proposal is recommended for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

\* This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

**Corina Crețu,**  
Commissioner for  
Regional Policy

**Carlos Moedas,**  
Commissioner for Research,  
Science and Innovation

Brussels, 21/06/2016